327 related articles for article (PubMed ID: 17323337)
1. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin.
Shirabe K; Itoh S; Yoshizumi T; Soejima Y; Taketomi A; Aishima S; Maehara Y
J Surg Oncol; 2007 Mar; 95(3):235-40. PubMed ID: 17323337
[TBL] [Abstract][Full Text] [Related]
2. New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma.
Shirabe K; Toshima T; Kimura K; Yamashita Y; Ikeda T; Ikegami T; Yoshizumi T; Abe K; Aishima S; Maehara Y
Liver Int; 2014 Jul; 34(6):937-41. PubMed ID: 24393295
[TBL] [Abstract][Full Text] [Related]
3. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value.
Shimada M; Yonemura Y; Ijichi H; Harada N; Shiotani S; Ninomiya M; Terashi T; Yoshizumi T; Soejima Y; Maehara Y
Transplant Proc; 2005 Mar; 37(2):1177-9. PubMed ID: 15848661
[TBL] [Abstract][Full Text] [Related]
4. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
[TBL] [Abstract][Full Text] [Related]
5. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
6. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
Tang W; Miki K; Kokudo N; Sugawara Y; Imamura H; Minagawa M; Yuan LW; Ohnishi S; Makuuchi M
Int J Oncol; 2003 May; 22(5):969-75. PubMed ID: 12684661
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
[TBL] [Abstract][Full Text] [Related]
8. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
[TBL] [Abstract][Full Text] [Related]
9. New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma: Predicting Prognosis After Living-donor Liver Transplantation.
Iguchi T; Shirabe K; Aishima S; Wang H; Fujita N; Ninomiya M; Yamashita Y; Ikegami T; Uchiyama H; Yoshizumi T; Oda Y; Maehara Y
Transplantation; 2015 Jun; 99(6):1236-42. PubMed ID: 25427164
[TBL] [Abstract][Full Text] [Related]
10. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation.
Taketomi A; Sanefuji K; Soejima Y; Yoshizumi T; Uhciyama H; Ikegami T; Harada N; Yamashita Y; Sugimachi K; Kayashima H; Iguchi T; Maehara Y
Transplantation; 2009 Feb; 87(4):531-7. PubMed ID: 19307789
[TBL] [Abstract][Full Text] [Related]
11. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.
Sumie S; Kuromatsu R; Okuda K; Ando E; Takata A; Fukushima N; Watanabe Y; Kojiro M; Sata M
Ann Surg Oncol; 2008 May; 15(5):1375-82. PubMed ID: 18324443
[TBL] [Abstract][Full Text] [Related]
12. Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma.
Kaibori M; Ishizaki M; Matsui K; Kwon AH
J Surg Oncol; 2010 Oct; 102(5):462-8. PubMed ID: 20872949
[TBL] [Abstract][Full Text] [Related]
13. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
[TBL] [Abstract][Full Text] [Related]
14. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
[TBL] [Abstract][Full Text] [Related]
16. Des-gamma-carboxy prothrombin (DCP) ratio is a useful prognostic tumor marker for single nodule hepatocellular carcinoma (HCC).
Murakami N; Tamano M; Yoneda M; Sugaya H; Hiraishi H
Hepatogastroenterology; 2008; 55(81):197-201. PubMed ID: 18507106
[TBL] [Abstract][Full Text] [Related]
17. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer.
Bertino G; Ardiri AM; Calvagno GS; Bertino N; Boemi PM
Drug News Perspect; 2010 Oct; 23(8):498-508. PubMed ID: 21031166
[TBL] [Abstract][Full Text] [Related]
19. Investigation of histological vascular invasion from preoperative evaluation in patients with hepatocellular carcinoma who underwent living donor liver transplantation.
Sakai K; Okajima H; Koshino K; Suzuki T; Nobori S; Matsuyama M; Ushigome H; Ochiai T; Yoshimura N
Transplant Proc; 2012 Mar; 44(2):409-11. PubMed ID: 22410029
[TBL] [Abstract][Full Text] [Related]
20. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers.
Toyoda H; Kumada T; Osaki Y; Oka H; Urano F; Kudo M; Matsunaga T
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1528-36. PubMed ID: 17162244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
